BioNTech reported a sharp 59.4 percent year-over-year revenue drop to €105.6 million for the second quarter, alongside a net loss of €820.8 million, according to the company’s financial disclosures.
Second-Quarter Financials and Guidance Reductions
The Mainz-based biotechnology firm saw its revenue contract from €260.8 million in the corresponding period of the previous year, while its net loss expanded to €3.24 per diluted share. According to corporate statements, the lowered expectations stem from a sharper-than-expected decline in demand for COVID-19 vaccines, Germany’s decision to utilize existing national vaccine stockpiles, and a delayed milestone payment tied to a licensed research partnership.
Reflecting these pressures, BioNTech adjusted its full-year 2026 revenue target down from its previous range of €2.0 billion to €2.3 billion. The company also adjusted its research and development spending guidance to a range of €2.0 billion to €2.3 billion, while maintaining its projected selling and administrative expenses between €700 million and €800 million.
Leadership Transition and Executive Changes
BioNTech announced that Guido Oelkers will succeed Ugur Sahin as chief executive officer no later than February 1, 2027. Oelkers joins from Swedish Orphan Biovitrum, where he served as chief executive. The incoming leadership change coincides with significant executive stock activity; Chief Operating Officer Sierk Poetting sold 50,000 shares for approximately $5.5 million via a pre-arranged trading plan following the earnings release.
Conversely, BioNTech continued its share repurchase program, buying back 1,693,056 American Depositary Shares during the second quarter. This brings the company’s cumulative spending under its $1.0 billion buyback authorization to $151.6 million.
Oncology Pipeline and Balance Sheet Strength
Despite near-term financial headwinds, BioNTech reported a cash and cash equivalents balance of €16.6 billion at the end of the quarter. Management anticipates a revenue recovery in the second half of the year, supported by a €613 million collaboration payment from Bristol Myers Squibb.
The company is advancing an extensive oncology pipeline that includes 14 registrational trials, with five focused on its lead candidate, Pumitamig. According to clinical development disclosures, BioNTech expects more than 17 registrational study readouts through 2030 and beyond. Key data milestones slated for the latter half of the year include an interim analysis for Gotistobart in squamous non-small cell lung cancer, a Phase III interim readout for BNT113 in head and neck tumors, and primary data for TPAM in breast cancer.
Related reading